[Fluconazole in the therapy of candidiasis in intensive care].
The authors studied four patients in ICU suffering from Candida infections who were treated with a new bis-triazole antimycotic, fluconazole. Various parameters of blood chemistry and blood and urine drug levels were monitored. After treatment all microbiological tests had become negative and clinical conditions had improved considerably within 30 to 60 days. No significant side effects were observed.
Niccolai
I
I
U.O. Anestesia e Rianimazione, Presidio Ospedaliero di Pistoia.
Paolini
P
P
Gironi
A
A
Lavacchi
L
L
Barontini
L
L
Aiardi
F
F
Caiano
G
G
Querci
A
A
Ferlito
A
A
D000368:Aged; D000369:Aged, 80 and over; D002177:Candidiasis / Q000188:drug therapy*; D003422:Critical Care; D004341:Drug Evaluation; D005260:Female; D015725:Fluconazole / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D015725:Fluconazole
Fluconazolo nella terapia delle candidosi in terapia intensiva.